Participated · Seed · May 2024

OverT Bio is a New York–based biotechnology company developing cellular therapies for solid tumors. The company leverages pooled functional screening and synthetic genomics platforms, OverT argetTM and OverT CRTM, to uncover therapeutic targets and genetic enhancements in an unbiased, data-driven way. Its goal is to deliver next-generation cell therapies for cancer patients underserved by current standard of care. OverT Bio was awarded a $120,000 G‑Rex Grant from ScaleReady in collaboration with Wilson Wolf Manufacturing, Bio‑Techne, and CellReady to support ongoing development. The grant provides no-cost support, access to GMP closed-system products, and ScaleReady expertise intended to accelerate development while ensuring future scalability and cost-effectiveness. The award is part of ScaleReady’s $20 million grant program aimed at advancing cell and gene-modified cell therapy development and manufacturing. OverT Bio develops engineered immune cell therapies for solid tumors using data-driven, high-throughput discovery platforms. The company employs massively parallel genetic screening, single-cell multiomic, and synthetic biology approaches to identify genomic modifications and novel receptors across the human genome. Its core platforms, OverTarget™ and OverTCR™, are designed to find safe, broadly applicable targets and to program immune cells with durable anti-tumor properties. OverT emphasizes patient-derived immune responses to discover receptors and targets that can be applied across the population. The company aims to advance preclinical assets toward curative, next-generation cellular therapies for advanced solid tumors. Funding will expand discovery platforms to address primary barriers to cell therapy durability and efficacy.

Participated · Seed · May 2024

Infinitopes combines AI-driven antigen discovery with high-efficiency viral vectors to build a scalable, off-the-shelf cancer vaccine platform. Its lead program, ITOP1, targets prevention of recurrence in oesophageal cancer and is entering a first-in-human, placebo-controlled Phase I/IIa study (VISTA) across multiple UK NHS university cancer centres. Supported by Cancer Research UK and embedded in Oxford University’s BioEscalator, the company has grown from three academic founders to roughly 20 full-time employees. Non-dilutive backing includes two maximum-size Innovate UK awards and an Innovative Licensing and Access Pathway passport from the MHRA. Beyond ITOP1, Infinitopes plans to expand its precision vaccine approach to additional solid tumours. To date the company has secured more than $35.1 million in equity financing from sector-focused investors such as Octopus Ventures, Amplify Bio, Cancer Research Horizons, Manta Ray Ventures and others. The fresh capital will fund the VISTA trial and further platform development.

Participated · Series B · Jul 2023

SURGE Therapeutics develops intraoperative immunotherapy using its SURGERx™ platform and an injectable biodegradable hydrogel to concentrate immunotherapy at surgical tumor resection sites. Its lead candidate, STM-416, is in a Phase 1/2a trial for recurrent bladder cancer, and the company recently dosed the first two patients. The intraoperative approach is intended to provide extended, localized release of immunotherapy to prevent tumor relapse and induce systemic antitumor immunity. In multiple aggressive murine models, intraoperative immunotherapy markedly improved survival relative to traditional systemic or local administration. SURGE plans to advance multiple clinical programs, expand the team, and generate proof-of-concept event-free survival data with its lead program. The company is based in Cambridge, MA. SURGE Therapeutics is developing an injectable biodegradable hydrogel (the SURGERx™ platform) that enables extended, localized release of cancer immunotherapy at the site of surgical tumor resection. The technology was built on research from founder and CEO Dr. Michael Goldberg's laboratory at Harvard Medical School. In multiple aggressive murine models, intraoperative delivery via the hydrogel vastly improved survival benefit relative to traditional systemic or local routes. SURGE seeks to reprogram the post-surgical immune response from immunosuppressive to immunostimulatory to destroy residual local and distal cancer cells and reduce recurrence. The company plans to use recent funding to accelerate development of its intraoperative immunotherapies, expand the team, and initiate clinical trials. SURGE is based in Cambridge, MA and has assembled a team of operators and advisors across localized therapeutics, translational immunotherapy, surgical oncology, and drug delivery.

Participated · Series A · Jul 2022

Cartography Biosciences develops antibody-based cancer therapies by integrating large-scale single-cell datasets with computational biology through its ATLAS and SUMMIT discovery platforms. The company aggregates petabyte-scale proprietary data from healthy tissues and tumor profiles and applies machine learning and AI to identify tumor-restricted antigens and antigen combinations. Its platform supports the design of logic-gated and highly selective antibody therapeutics aimed at improving specificity and therapeutic index. Cartography is advancing a pipeline of oncology programs with its lead candidate, CBI-1214, a T-cell engager for colorectal cancer that entered clinical testing in early 2026 and is currently enrolling patients in a Phase 1 trial. The company stated that the strategic investment from Samsung Ventures will help accelerate its oncology programs and expand its drug discovery capabilities.